Table 1.
Patient characteristics, management and outcomes
| Group 1 Observation or symptomatic relief n = 34 | Group 2 Prophylactic dose anticoagulation† n = 34 | Group 3 Intermediate or therapeutic dose anticoagulation‡ n = 25 | ||
|---|---|---|---|---|
| Patient | Median age (range, years) | 63.8 (29.3–88) | 60.8 (25.5–90.5) | 48.9 (20.3–89) |
| Male, n (%) | 26 (74) | 20 (59) | 9 (36) | |
| Cancer, n (%) | 11 (32) | 4 (12) | 8 (32) | |
| Infection, n (%) | 4 (12) | 15 (44) | 7 (28) | |
| No cancer or infection, n (%) | 19 (56) | 15 (44) | 10 (40) | |
| Thrombus | Single segment ≥ 5 cm, n (%) | 25 (74) | 25 (74) | 17 (68) |
| Proximal to cubital fossa, n (%) | 22 (65) | 26 (76) | 10 (40) | |
| Treatment | Duration (weeks, median, range) | NA | 1.07 (0.1–25) | 3 (0.6–31.9) |
| Treatment outcomes | Thrombus resolution, n/n (post‐treatment ultrasounds) | 0/6 | 2/8 | 5/14 |
| Thrombus extension, n/n (post‐treatment ultrasounds) | 0/6 | 0/8 | 2/14 | |
| Bleeding, n (%) | 0 | 0 | 1 (4) |
†
Prophylactic dose = enoxaparin 40 mg daily or equivalent if dose reduction required due to body weight/renal function.
‡
intermediate/therapeutic anticoagulation = greater than prophylactic dose, for example, enoxaparin 40 mg, up to enoxaparin 1 mg/kg BD.
NA, not applicable.